

Magdalena Bujalska-ZadroÅ¼ny

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4440454/publications.pdf>

Version: 2024-02-01

63
papers

569
citations

623734

14
h-index

839539

18
g-index

63
all docs

63
docs citations

63
times ranked

980
citing authors

#	ARTICLE	IF	CITATIONS
1	Matrix metalloproteinase-3 serum levels in schizophrenic patients. <i>International Journal of Psychiatry in Clinical Practice</i> , 2023, 27, 1-7.	2.4	3
2	Manganese concentration in patients with encephalopathy following ephedrone use: a narrative review and analysis of case reports. <i>Clinical Toxicology</i> , 2022, 60, 10-17.	1.9	4
3	Gold (III) Derivatives in Colon Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 724.	4.1	22
4	Polypharmacotherapy in Psychiatry: Global Insights from a Rapid Online Survey of Psychiatrists. <i>Journal of Clinical Medicine</i> , 2022, 11, 2129.	2.4	0
5	Design, Synthesis, and Biological Evaluation of a Series of 5- and 7-Hydroxycoumarin Derivatives as 5-HT _{1A} Serotonin Receptor Antagonists. <i>Pharmaceutics</i> , 2021, 14, 179.	3.8	2
6	Synthesis, docking studies, and pharmacological evaluation of 2-(4-hydroxypropyl)-4-crylpiperazine derivatives as serotonergic ligands. <i>Archiv Der Pharmazie</i> , 2021, 354, 2000414.	4.1	7
7	Loss of Brain-Derived Neurotrophic Factor (BDNF) Resulting From Congenital- Or Mild Traumatic Brain Injury-Induced Blood-Brain Barrier Disruption Correlates With Depressive-Like Behaviour. <i>Neuroscience</i> , 2021, 458, 1-10.	2.3	9
8	Evaluation of tramadol human pharmacokinetics and safety after co-administration of magnesium ions in randomized, single- and multiple-dose studies. <i>Pharmacological Reports</i> , 2021, 73, 604-614.	3.3	2
9	Insulin, but Not Metformin, Supports Wound Healing Process in Rats with Streptozotocin-Induced Diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 1505-1517.	2.4	4
10	Disulfiram Abrogates Morphine Tolerance—A Possible Role of μ -Opioid Receptor-Related G-Protein Activation in the Striatum. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4057.	4.1	3
11	Pharmacotherapy of Patients Taking New Psychoactive Substances: A Systematic Review and Analysis of Case Reports. <i>Frontiers in Psychiatry</i> , 2021, 12, 669921.	2.6	5
12	Increasing the Effectiveness of Pharmacotherapy in Psychiatry by Using a Pharmacological Interaction Database. <i>Journal of Clinical Medicine</i> , 2021, 10, 2185.	2.4	1
13	The Influence of Cross-Fostering on Alcohol Consumption and Depressive-Like Behaviors in HA and LA Mice: The Role of the Endogenous Opioid System. <i>Brain Sciences</i> , 2021, 11, 622.	2.3	2
14	Psychoactive Substances Taken with Mephedrone and HCV Infection. <i>Journal of Clinical Medicine</i> , 2021, 10, 3218.	2.4	1
15	Nitric oxide modulates tapentadol antinociceptive tolerance and physical dependence. <i>European Journal of Pharmacology</i> , 2021, 907, 174245.	3.5	5
16	The Positive and Negative Outcome of Morphine and Disulfiram Subacute Co-Administration in Rats in the Absence of Ethanol Challenge. <i>Pharmaceutics</i> , 2021, 13, 29.	4.5	3
17	Magnesium and Morphine in the Treatment of Chronic Neuropathic Pain—A Biomedical Mechanism of Action. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13599.	4.1	7
18	Optimisation of methadone treatment in a group of patients on a mephedrone binge and dependent on many psychoactive substances. <i>International Journal of Psychiatry in Clinical Practice</i> , 2020, 24, 38-42.	2.4	3

#	ARTICLE	IF	CITATIONS
19	G protein-coupled receptor binding and pharmacological evaluation of indole-derived thiourea compounds. <i>Archiv Der Pharmazie</i> , 2020, 353, 1900218.	4.1	2
20	Identification of a Potent and Selective 5-HT _{1A} Receptor Agonist with <i>In Vitro</i> and <i>In Vivo</i> Antinociceptive Activity. <i>ACS Chemical Neuroscience</i> , 2020, 11, 4111-4127.	3.5	8
21	Mosaic Recombinant Adeno-associated Virus Vector rAAV/DJ/CAG for Targeted Gene Delivery to Melanoma Cells Metastasized to the Lung. <i>Anticancer Research</i> , 2020, 40, 4425-4444.	1.1	4
22	6-Acetyl-5-hydroxy-4,7-dimethylcoumarin derivatives: Design, synthesis, modeling studies, 5-HT _{1A} , 5-HT _{2A} and D ₂ receptors affinity. <i>Bioorganic Chemistry</i> , 2020, 100, 103912.	4.1	8
23	Novel opioid-neurotensin-based hybrid peptide with spinal long-lasting antinociceptive activity and a propensity to delay tolerance development. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1440-1452.	12.0	4
24	Effectiveness of the methadone programme in the treatment of patients on a mephedrone binge and dependent on heroin: a retrospective study, 2010-19. <i>International Journal of Psychiatry in Clinical Practice</i> , 2020, 24, 322-327.	2.4	2
25	The Psychiatric Characteristics of People on a Mephedrone (bath salts) Binge. <i>Substance Use and Misuse</i> , 2020, 55, 1610-1617.	1.4	6
26	New antihistamines – perspectives in the treatment of some allergic and inflammatory disorders. <i>Archives of Medical Science</i> , 2019, 15, 537-553.	0.9	22
27	Divergent Response to Cannabinoid Receptor Stimulation in High and Low Stress-Induced Analgesia Mouse Lines Is Associated with Differential G-Protein Activation. <i>Neuroscience</i> , 2019, 404, 246-258.	2.3	9
28	Neurokinin-1 receptor-based bivalent drugs in pain management: The journey to nowhere?. , 2019, 196, 44-58.		15
29	Bidirectional selection for high and low stress-induced analgesia affects G-protein activity. <i>Neuropharmacology</i> , 2019, 144, 37-42.	4.1	13
30	Disulfiram attenuates morphine or methadone withdrawal syndrome in mice. <i>Behavioural Pharmacology</i> , 2018, 29, 393-399.	1.7	5
31	Level of magnesium in psychiatry – What is the cause of ambiguous results?. <i>General Hospital Psychiatry</i> , 2018, 51, 136.	2.4	2
32	Inhibitory effect of <i>Ligustrum vulgare</i> leaf extract on the development of neuropathic pain in a streptozotocin-induced rat model of diabetes. <i>Phytomedicine</i> , 2018, 49, 75-82.	5.3	17
33	Awareness and attitudes towards clinical trials among Polish oncological patients who had never participated in a clinical trial. <i>Advances in Clinical and Experimental Medicine</i> , 2018, 27, 525-529.	1.4	7
34	Patient knowledge on reporting adverse drug reactions in Poland. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 47-53.	1.8	6
35	Antinociceptive effect of co-administered NMDA and histamine H ₄ receptor antagonists in a rat model of acute pain. <i>Pharmacological Reports</i> , 2017, 69, 222-228.	3.3	6
36	Magnesium in schizophrenia. <i>Pharmacological Reports</i> , 2017, 69, 929-934.	3.3	16

#	ARTICLE	IF	CITATIONS
37	Delta-opioid receptor antagonism leads to excessive ethanol consumption in mice with enhanced activity of the endogenous opioid system. <i>Neuropharmacology</i> , 2017, 118, 90-101.	4.1	14
38	Naloxone exacerbates memory impairments and depressive-like behavior after mild traumatic brain injury (mTBI) in mice with upregulated opioid system activity. <i>Behavioural Brain Research</i> , 2017, 326, 209-216.	2.2	13
39	Ionized magnesium in plasma and erythrocytes for the assessment of low magnesium status in alcohol dependent patients. <i>Drug and Alcohol Dependence</i> , 2017, 178, 271-276.	3.2	15
40	Magnesium enhances opioid-induced analgesia – What we have learnt in the past decades?. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 99, 113-127.	4.0	36
41	The Discovery and Development of Drug Combinations for the Treatment of Various Diseases from Patent Literature (1980-Present). <i>Current Topics in Medicinal Chemistry</i> , 2017, 17, 875-894.	2.1	6
42	New agents approved for treatment of acute staphylococcal skin infections. <i>Archives of Medical Science</i> , 2016, 6, 1327-1336.	0.9	17
43	Esculetin reduces leukotriene B4 level in plasma of rats with adjuvant-induced arthritis. <i>Reumatologia</i> , 2016, 54, 161-164.	1.1	19
44	Micronized Organic Magnesium Salts Enhance Opioid Analgesia in Rats. <i>PLoS ONE</i> , 2016, 11, e0161776.	2.5	1
45	Biphalin preferentially recruits peripheral opioid receptors to facilitate analgesia in a mouse model of cancer pain - A comparison with morphine. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 89, 39-49.	4.0	13
46	Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?. <i>Neurotoxicity Research</i> , 2016, 30, 698-714.	2.7	2
47	Antinociceptive effect induced by a combination of opioid and neurotensin moieties vs. their hybrid peptide [Ile 9]PK20 in an acute pain treatment in rodents. <i>Brain Research</i> , 2016, 1648, 172-180.	2.2	14
48	Biological evaluation and molecular docking studies of AA3052, a compound containing a μ -selective opioid peptide agonist DALDA and d-Phe-Phe-d-Phe-Leu-Leu-NH ₂ , a substance P analogue. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 93, 11-20.	4.0	8
49	Central antinociceptive effect of tapentadol is increased by nitric oxide synthase inhibitors. <i>Behavioural Pharmacology</i> , 2016, 27, 606-614.	1.7	7
50	Synthesis and binding characteristics of [3H]neuromedin N, a NTS2 receptor ligand. <i>Neuropeptides</i> , 2016, 57, 15-20.	2.2	3
51	Antinociceptive activity of intraperitoneally administered novel and potent anticonvulsive compound, CY-PROLL-SS, in animal neuropathic pain models. <i>Pharmacological Reports</i> , 2016, 68, 601-607.	3.3	3
52	Cannabinoid Ligands and Alcohol Addiction: A Promising Therapeutic Tool or a Humbug?. <i>Neurotoxicity Research</i> , 2016, 29, 173-196.	2.7	22
53	Antinociceptive properties of esculetin in non-inflammatory and inflammatory models of pain in rats. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 213-219.	1.9	19
54	Tapentadol and nitric oxide synthase systems. <i>Behavioural Pharmacology</i> , 2015, 26, 282-288.	1.7	9

#	ARTICLE	IF	CITATIONS
55	Effects of the Hybridization of Opioid and Neurotensin Pharmacophores on Cell Survival in Rat Organotypic Hippocampal Slice Cultures. <i>Neurotoxicity Research</i> , 2015, 28, 352-360.	2.7	12
56	Influence of nitric oxide synthase or cyclooxygenase inhibitors on cannabinoids activity in streptozotocin-induced neuropathy. <i>Pharmacological Reports</i> , 2015, 67, 209-216.	3.3	16
57	Mechanisms of morphine-venlafaxine interactions in diabetic neuropathic pain model. <i>Pharmacological Reports</i> , 2015, 67, 90-96.	3.3	5
58	Additive Effect of Combined Application of Magnesium and MK-801 on Analgesic Action of Morphine. <i>Pharmacology</i> , 2014, 93, 113-119.	2.2	11
59	Enhancement of antinociceptive effect of morphine by antidepressants in diabetic neuropathic pain model. <i>Pharmacological Reports</i> , 2014, 66, 228-234.	3.3	17
60	Dose-dependending effect of intracerebroventricularly administered bradykinin on nociception in rats. <i>Pharmacological Reports</i> , 2013, 65, 1006-1011.	3.3	8
61	Venlafaxine and Neuropathic Pain. <i>Pharmacology</i> , 2013, 91, 69-76.	2.2	21
62	Modification of morphine analgesia by venlafaxine in diabetic neuropathic pain model. <i>Pharmacological Reports</i> , 2012, 64, 1267-1275.	3.3	14
63	Influence of acute and subchronic oral administration of dehydroepiandrosterone (DHEA) on nociceptive threshold in rats. <i>Pharmacological Reports</i> , 2012, 64, 965-969.	3.3	9